Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P860004/S464

SynchroMed Infusion System, Ascenda Intrathecal Catheters TDD (Drug Delivery Infusion Pump 8667), TDD (Drug Delivery I

Medtronic, Inc. · Decision date Oct 29, 2026

MEDTECHLEDGER EXPLANATIONP860004/S464

What did the FDA decide?

The FDA record lists this 30-Day Notice under P860004/S464 as a process change for a manufacturer, sterilizer, packager or supplier, tied to the SynchroMed Infusion System and Ascenda Intrathecal Catheters. The decision is OK30. The statement covers six revisions, including enhanced operator verification of the FactoryWorks processing step and recorded battery pre-weight, added pre-weight and post-weight out-of-control action plans, and software and HMI updates that automatically reject batteries above the established final-fill reasonable limit.

The statement also covers white work-in-progress trays for electrolyte-filled batteries, an isopropyl alcohol wipe for residual electrolyte, and removal of Ball Press and Button Press certification prerequisites from the ram-change procedure. The identifier links the supplement to the original PMA; the notice itself does not approve the whole system. The record does not provide supporting data, safety or effectiveness findings beyond these described changes.

Whether the removed prerequisites were matched by other process controls is not evident from the statement alone; that specific information is absent.

FDA approval order statement

1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General Hospital
Decision date
Oct 29, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P860004/S464
Regulatory pathway
PMA supplement
Product code
LKK
Decision code
OK30
Decision date
Oct 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pump, infusion, implanted, programmable.

Product code
LKK
FDA device class
3

For the original device and its historical approval scope, see PMA P860004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P860004 · Original PMA

    MEDTRONIC(R) SYNCHROMED(TM) PUMP & INFUSION SYSTEM

  2. P860004/S464 received

    Application receipt date recorded by FDA.

  3. P860004/S462 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  4. P860004/S458 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  5. P860004/S464 · FDA decision

    30-Day Notice

  6. P860004/S465 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

Timeline entries are records held by MedtechLedger for P860004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P860004

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalMar 14, 1988FDA
Medtronic, Inc.PMA supplementOct 16, 2026FDA
Medtronic, Inc.PMA supplementOct 27, 2026FDA
Medtronic, Inc.PMA supplementOct 30, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
7000 Central Ave., NE, Minneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records